A Phase 1 Study to Assess the Effect of Itraconazole on ABBV-722 in Healthy Adult Participants
A Phase 1 Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics, Safety, and Tolerability of ABBV-722 in Healthy Adult Subjects
The objective of this study is to assess the effect of repeated doses of itraconazole on the single dose pharmacokinetics (PK) of ABBV-722.
研究概览
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
Illinois
-
Grayslake、Illinois、美国、60030
- Acpru /Id# 282143
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Laboratory values meet the criteria specified in the protocol.
- A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead electrocardiogram (ECG).
Exclusion Criteria:
- History of any clinically significant illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study treatment.
- Consumption of alcohol, grapefruit products, Seville oranges, starfruit products or quinine/tonic water within the 72-hour period prior to study treatment administration.
- Use of tobacco- or nicotine-containing products within 3 months (90 days) prior to the first dose of study treatment.
- Participant has prior exposure to ABBV-722 within 90 days prior to the first dose of study treatment.
学习计划
研究是如何设计的?
设计细节
- 主要用途:基础科学
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Period 1 & 2
In Period 1, participants will receive a single dose of ABBV-722. In Period 2, participants will receive multiple daily doses of Itraconazole and a single dose of ABBV-722. |
Oral Tablet Oral Capsule |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Maximum Observed Plasma Concentration (Cmax) of ABBV-722
大体时间:Up to Day 8 in Period 1 and Up to Day 14 in Period 2
|
Cmax of ABBV-722 |
Up to Day 8 in Period 1 and Up to Day 14 in Period 2
|
|
Time to Cmax (Tmax) of ABBV-722
大体时间:Up to Day 8 in Period 1 and Up to Day 14 in Period 2
|
Tmax of ABBV-722 |
Up to Day 8 in Period 1 and Up to Day 14 in Period 2
|
|
Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Measurable Concentration (AUCt) of ABBV-722
大体时间:Up to Day 8 in Period 1 and Up to Day 14 in Period 2
|
AUCt of ABBV-722 |
Up to Day 8 in Period 1 and Up to Day 14 in Period 2
|
|
Area Under the Plasma Concentration-Time Curve From Time 0 to Infinite Time (AUCinf) of ABBV-722
大体时间:Up to Day 8 in Period 1 and Up to Day 14 in Period 2
|
AUCinf of ABBV-722 |
Up to Day 8 in Period 1 and Up to Day 14 in Period 2
|
|
Terminal Phase Elimination Rate Constant (β) of ABBV-722
大体时间:Up to Day 8 in Period 1 and Up to Day 14 in Period 2
|
β of ABBV-722 |
Up to Day 8 in Period 1 and Up to Day 14 in Period 2
|
|
Terminal Phase Elimination Half-Life (t1/2) of ABBV-722
大体时间:Up to Day 8 in Period 1 and Up to Day 14 in Period 2
|
t1/2 of ABBV-722 |
Up to Day 8 in Period 1 and Up to Day 14 in Period 2
|
|
Number of Participants with Adverse Events (AEs)
大体时间:Up to Approximately 45 Days
|
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. |
Up to Approximately 45 Days
|
合作者和调查者
赞助
调查人员
- 研究主任:ABBVIE INC.、AbbVie
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.